Affinity Asset Advisors »

Travere Therapeutics shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Travere Therapeutics shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Travere Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Travere Therapeutics held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Travere Therapeutics by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-09-30 $4.3M 5.0M 0.86

More positions owned by Affinity Asset Advisors

Xenon Pharmaceuticals (XENE)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Cassava Sciences Put Option (SAVA)
Apogee Therapeutics (APGE)
Nuvalent Inc-a (NUVL)
Arcellx Common Stock (ACLX)
Alkermes SHS (ALKS)
Madrigal Pharmaceuticals (MDGL)
Crinetics Pharmaceuticals In (CRNX)
Nurix Therapeutics (NRIX)
Vera Therapeutics Cl A (VERA)
Verona Pharma Sponsored Ads (VRNA)
Autolus Therapeutics Spon Ads (AUTL)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Inozyme Pharma (INZY)

View all positions for Affinity Asset Advisors

Top funds holding Travere Therapeutics

Wolverine Asset Management
D. E. Shaw & Co
Oaktree Capital Management
Graham Capital Management
Silverback Asset Management
Capstone Investment Advisors
Highbridge Capital Management
CNH Partners
Point72 Asset Management
Lazard Asset Management
Readystate Asset Management
Affinity Asset Advisors
Agf Management
Advent Capital Management
BlackRock

View all funds holding Travere Therapeutics